Canada markets closed

Aequus Pharmaceuticals Inc. (AQS.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.0200-0.0050 (-20.00%)
At close: 10:53AM EDT

Aequus Pharmaceuticals Inc.

200 Granville Street
Suite 2820
Vancouver, BC V6C 1S4
604 336 7906

IndustryDrug Manufacturers - Specialty & Generic
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Douglas Glen JanzenChairman, CEO & President206.25kN/A1969
Ms. Ann Fehr CGA, CPACFO & Corporate Secretary136.13kN/A1969
Mr. Grant LarsenChief Commercial Officer244.58kN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.


Aequus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease. The company was incorporated in 2013 and is headquartered in Vancouver, Canada.

Corporate Governance

Aequus Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.